Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324850 | 0.84 | ASIC3 (0.53) | GRM5ASIC3KCNH2COMTPIK3CD | |
| SCHEMBL20625350 | 0.79 | BACE1 (0.46) | GRM5CYP2A6ATMASIC3BACE1 | |
| SCHEMBL20602041 | 0.79 | BACE1 (0.47) | GRM5CYP2A6ASIC3BACE1KCNH2 | |
| SCHEMBL4309708 | 0.79 | CYP17A1 (0.53) | GRM5ASIC3 | |
| SCHEMBL7921223 | 0.79 | GRM5 (0.53) | GRM5ASIC3 | |
| SCHEMBL4410475 | 0.79 | GRM5 (0.52) | GRM5PIK3CDPIK3CAMTORPIK3CG | |
| SCHEMBL20603203 | 0.78 | GRM5 (0.47) | GRM5CYP2A6ATMBACE1KCNH2 | |
| SCHEMBL22025844 | 0.78 | GRM5 (0.44) | GRM5CYP2A6ATMBACE1KCNH2 | |
| SCHEMBL16108938 | 0.77 | CYP2A6 (0.54) | GRM5CYP2A6ASIC3COMT | |
| SCHEMBL18890284 | 0.77 | IDO1 (0.56) | GRM5ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| WO-2019005297-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN2 | GRM5 297/4885CYP2A6 1586/4885ATM 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.